Startseite BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience

  • Francesca Galuppini , Gianmaria Pennelli EMAIL logo , Federica Vianello , Simona Censi , Laura Zambonin , Sara Watutantrige-Fernando , Jacopo Manso , Davide Nacamulli , Ornella Lora , Maria Rosa Pelizzo , Massimo Rugge , Susi Barollo und Caterina Mian
Veröffentlicht/Copyright: 10. Februar 2016
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 54 Heft 9

Abstract

Background:

Risk stratification in patients with papillary thyroid carcinoma (PTC) currently relies on postoperative parameters. Testing for BRAF mutations preoperatively may serve as a novel tool for identifying PTC patients at risk of persistence/recurrence after surgery.

Methods:

The study involved 185 consecutive patients with a histological diagnosis of PTC and BRAF analysis performed on thyroid fine-needle aspiration biopsy (FNAB). We assessed BRAF status in FNAB specimens obtained before thyroidectomy for PTC, and examined its association with the clinicopathological characteristics identified postoperatively, and with outcome after a mean 55±15 months of follow-up.

Results:

One hundred and fifteen of 185 (62%) PTCs carried a BRAF mutation. Univariate analysis showed that BRAF status correlated with the histological variant of PTC, cancer size, and stage at diagnosis, but not with gender, age, multifocality, or lymph node involvement. BRAF-mutated cases had a higher prevalence of persistent/recurrent disease by the end of the follow-up (11% vs. 8%), but this difference was not statistically significant. The Kaplan-Meier curve shows that among the patients with persistent/recurrent disease, BRAF-mutated patients needed a second treatment earlier than patients with BRAF wild-type, although the difference did not completely reach the statistical significance.

Conclusions:

Our study confirmed that preoperatively-identified BRAF mutation are associated with certain pathological features of PTC that correlate with prognosis. We speculate that it has a role in identifying PTCs that would generally be considered low-risk but that may reveal an aggressive behavior during their follow-up.

Keywords: BRAF; FNAB; prognosis; thyroid cancer
Corresponding author: Dr. Gianmaria Pennelli, Pathology Unit, Department of Medicine-DIMED, Via A. Gabelli n.63, 35121 Padova, Italy, Phone: (+39)049.8218996, Fax: (+39)049.8211319, E-mail: ; and Department of Medicine (DIMED), Surgical Pathology and Cytopathology Unit, University of Padova, Padova, Italy
aFrancesca Galuppini and Gianmaria Pennelli contributed equally to this work.

Acknowledgments

We thank Frances Coburn for text editing.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. J Am Med Assoc 2006;295: 2164–7.10.1001/jama.295.18.2164Suche in Google Scholar

2. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056–60.10.1089/thy.2004.14.1056Suche in Google Scholar

3. Mazzaferri EL. An overview of the management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P, editors. Practical management of thyroid cancer: a multidisciplinary approach. London: Springer-Verlag, 2006:1–28.10.1007/b136179Suche in Google Scholar

4. Ries LA, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2004/.Pdf. Assesed: November 2006.Suche in Google Scholar

5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–42.10.1089/thy.2006.16.109Suche in Google Scholar

6. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407–27.10.1093/jnci/dji289Suche in Google Scholar

7. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.10.1210/jcem.86.4.7407Suche in Google Scholar

8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–28.10.1016/0002-9343(94)90321-2Suche in Google Scholar

9. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2005;3: 404–57.Suche in Google Scholar

10. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414–24.10.1210/jcem-71-2-414Suche in Google Scholar

11. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, CooperDS, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012–21.10.1002/(SICI)1097-0142(19980901)83:5<1012::AID-CNCR28>3.0.CO;2-9Suche in Google Scholar

12. Tanaka K, Sonoo H, Hirono M, Ohkubo S, Nomura T, Ikeda M, et al. Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg Today 2005;35:714–19.10.1007/s00595-005-3021-8Suche in Google Scholar

13. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163–72.10.1385/EP:16:3:163Suche in Google Scholar

14. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742–62.10.1210/er.2007-0007Suche in Google Scholar

15. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867–72.10.1210/jc.2003-032050Suche in Google Scholar

16. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761–5.10.1158/1078-0432.CCR-03-0273Suche in Google Scholar

17. Domingues R, Mendonca E, Sobrinho L, Bugalho MJ. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005;16:27–31.10.1111/j.1365-2303.2004.00223.xSuche in Google Scholar

18. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136–43.10.1097/01.pdm.0000213461.53021.84Suche in Google Scholar

19. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cytopathology diagnosis, especially in BRAF600E mutation prevalent area. Clin Endocrinol 2006;65:660–6.10.1111/j.1365-2265.2006.02646.xSuche in Google Scholar

20. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092–8.10.1210/jc.2009-0247Suche in Google Scholar

21. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006;244:799–804.10.1097/01.sla.0000224751.80858.13Suche in Google Scholar

22. Mojica WD, Khoury T. Presence of the BRAF V600E point mutation in morphologically benign appearing thyroid inclusions of cervical lymph nodes. Endocr Pathol 2006;17:183–9.10.1385/EP:17:2:183Suche in Google Scholar

23. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006;65:364–8.10.1111/j.1365-2265.2006.02605.xSuche in Google Scholar

24. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83–95.10.1586/14737159.8.1.83Suche in Google Scholar

25. UICC: Thyroid gland. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant rumours, 7th ed. Oxford, UK: Wiley-Blackwell Publishers, 2009:58–62.Suche in Google Scholar

26. Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, et al. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. Clin Oncol (R Coll Radiol) 2012;24:162–8.10.1016/j.clon.2011.02.011Suche in Google Scholar

27. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006;154:341–8.10.1530/eje.1.02072Suche in Google Scholar

28. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245–62.10.1677/erc.1.0978Suche in Google Scholar

29. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455–64.10.1677/erc.1.01086Suche in Google Scholar

30. Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol 2007;51:736–47.10.1590/S0004-27302007000500011Suche in Google Scholar

31. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191–205.10.1677/ERC-07-0212Suche in Google Scholar

32. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas. Verh Dt Ges Pathol 1997;81: 82–96.Suche in Google Scholar

33. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564–73.10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0Suche in Google Scholar

34. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009;161:467–73.10.1530/EJE-09-0353Suche in Google Scholar

35. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005;90:3028–35.10.1210/jc.2004-1394Suche in Google Scholar PubMed

36. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol 2011;24(Suppl 2):S34–43.10.1038/modpathol.2010.167Suche in Google Scholar PubMed

37. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 2012;97: E1758–65.10.1210/jc.2012-1269Suche in Google Scholar PubMed

38. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer 2011;117:4390–5.10.1002/cncr.26072Suche in Google Scholar PubMed PubMed Central

39. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280–4.10.1210/jc.2004-0172Suche in Google Scholar PubMed

40. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320–5.10.1089/thy.2005.15.320Suche in Google Scholar PubMed

41. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, et al. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 2010;17:1839–50.10.2174/092986710791111189Suche in Google Scholar PubMed

42. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373–9.10.1210/jc.2005-0987Suche in Google Scholar PubMed

43. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010;32:38–45.Suche in Google Scholar

44. Ugolini C, GianniniR, Lupi C, Salvatore G, Miccoli P, Proietti A, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007;17:381–8.10.1089/thy.2006.0305Suche in Google Scholar PubMed

45. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004;25:1729–35.10.3892/ijo.25.6.1729Suche in Google Scholar

46. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588–93.10.1111/j.1365-2265.2005.02389.xSuche in Google Scholar PubMed

47. Knauf JA, Ma X, Smith EP, Khang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238–45.10.1158/0008-5472.CAN-05-0047Suche in Google Scholar PubMed

48. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38–46.10.1002/cncr.22754Suche in Google Scholar PubMed

49. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005;352:2406–12. Erratum in: N Engl J Med 2005;353:1640.10.1056/NEJMoa044190Suche in Google Scholar PubMed

50. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006;107:1831–8.10.1002/cncr.22218Suche in Google Scholar PubMed

51. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90.10.1016/j.cell.2014.09.050Suche in Google Scholar PubMed PubMed Central

52. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393–7.10.1210/jc.2003-030305Suche in Google Scholar PubMed

53. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466–71.10.1097/SLA.0b013e318148563dSuche in Google Scholar PubMed PubMed Central

54. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012;97:1745–9.10.1210/jc.2012-1526Suche in Google Scholar PubMed

55. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015;33:42–50.10.1200/JCO.2014.56.8253Suche in Google Scholar PubMed PubMed Central

56. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, et al. PTC Study Group. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab 2013;98:636–42.10.1210/jc.2012-3401Suche in Google Scholar PubMed

57. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008;159:659–67.10.1530/EJE-07-0896Suche in Google Scholar PubMed

58. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012;97:4390–8.10.1210/jc.2012-1775Suche in Google Scholar PubMed

Received: 2015-3-3
Accepted: 2015-12-27
Published Online: 2016-2-10
Published in Print: 2016-9-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. The Theranos phenomenon, scientific transparency and freedom of speech
  4. Holotranscobalamin: in the middle of difficultly lies opportunity
  5. Review
  6. Laboratory and clinical risk assessment to treat myelodysplatic syndromes
  7. Mini Review
  8. Quantitative nucleic acid amplification by digital PCR for clinical viral diagnostics
  9. Genetics and Molecular Diagnostics
  10. Hybrid minigene splicing assay verified the pathogenicity of a novel splice site variant in the dystrophin gene of a Chinese patient with typical Duchenne muscular dystrophy phenotype
  11. General Clinical Chemistry and Laboratory Medicine
  12. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension
  13. Sex steroid hormone stability in serum tubes with and without separator gels
  14. Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: a preliminary study of plasma sterols
  15. An International Standard for holotranscobalamin (holoTC): international collaborative study to assign a holoTC value to the International Standard for vitamin B12 and serum folate
  16. A technical and clinical evaluation of a new assay for inhibin A and its use in second trimester Down syndrome screening
  17. Investigation on the ability of first trimester glycodelin and angiopoietin-2 to predict small-for-gestational age pregnancies at delivery
  18. Plasma total C-terminal agrin fragment (tCAF) as a marker for kidney function in patients with chronic kidney disease
  19. Hematology and Coagulation
  20. Thirty-minutes’ exposure to smartphone call triggers neutrophil activation in vitro
  21. Performance of the XN-2000 WPC channel-flagging to differentiate reactive and neoplastic leukocytosis
  22. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation
  23. Reference Values and Biological Variations
  24. Derivation of level-specific reference change values (RCV) from a health screening database and optimization of their thresholds based on clinical utility
  25. Cancer Diagnosis
  26. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience
  27. Letters to the Editor
  28. Significant increase of serum prostate-specific antigen after exercise
  29. Serum delipidation but not high-speed centrifugation is effective in clearing lipemia interference in serum lipase activity measurement
  30. A relationship between absolute monocyte count and C-reactive protein in patients with migraine undergoing no pharmacological therapy
  31. Validation of the “Vacutainer® urinalysis preservative plus urine tube” for the determination of albumin and protein
  32. Performance evaluation of a novel automated HIV Ag/Ab chemiluminescence immunoassay
  33. SLC26A4 genotypes associated with enlarged vestibular aqueduct malformation in south Italian children with sensorineural hearing loss
  34. Is cystatin C level altered in women with polycystic ovary syndrome?
  35. Venous thromboembolism in a patient with persistent inhibitor to coagulation factor V – a case report
  36. Free light chains nephelometric assay: human urine stability in different storage conditions
  37. Comparing the viscoelastomeric fibrin polymerization assays FIBTEM® (ROTEM) vs. Functional Fibrinogen® (TEG): or why is a higher threshold for fibrinogen substitution better than a lower one?
  38. Reply to: Comparing the visco-elastomeric fibrin polymerization assays FIBTEM® (ROTEM) vs. Functional Fibrinogen® (TEG): or why is a higher threshold for fibrinogen substitution better than a lower one? By Schöchl et al.
  39. Congress Abstracts
  40. 5th Slovenian Congress of Clinical Chemistry and Laboratory Medicine
https://doi.org/10.1515/cclm-2015-0218
Schlagwörter für diesen Artikel
BRAF; FNAB; prognosis; thyroid cancer

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. The Theranos phenomenon, scientific transparency and freedom of speech
  4. Holotranscobalamin: in the middle of difficultly lies opportunity
  5. Review
  6. Laboratory and clinical risk assessment to treat myelodysplatic syndromes
  7. Mini Review
  8. Quantitative nucleic acid amplification by digital PCR for clinical viral diagnostics
  9. Genetics and Molecular Diagnostics
  10. Hybrid minigene splicing assay verified the pathogenicity of a novel splice site variant in the dystrophin gene of a Chinese patient with typical Duchenne muscular dystrophy phenotype
  11. General Clinical Chemistry and Laboratory Medicine
  12. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension
  13. Sex steroid hormone stability in serum tubes with and without separator gels
  14. Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: a preliminary study of plasma sterols
  15. An International Standard for holotranscobalamin (holoTC): international collaborative study to assign a holoTC value to the International Standard for vitamin B12 and serum folate
  16. A technical and clinical evaluation of a new assay for inhibin A and its use in second trimester Down syndrome screening
  17. Investigation on the ability of first trimester glycodelin and angiopoietin-2 to predict small-for-gestational age pregnancies at delivery
  18. Plasma total C-terminal agrin fragment (tCAF) as a marker for kidney function in patients with chronic kidney disease
  19. Hematology and Coagulation
  20. Thirty-minutes’ exposure to smartphone call triggers neutrophil activation in vitro
  21. Performance of the XN-2000 WPC channel-flagging to differentiate reactive and neoplastic leukocytosis
  22. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation
  23. Reference Values and Biological Variations
  24. Derivation of level-specific reference change values (RCV) from a health screening database and optimization of their thresholds based on clinical utility
  25. Cancer Diagnosis
  26. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience
  27. Letters to the Editor
  28. Significant increase of serum prostate-specific antigen after exercise
  29. Serum delipidation but not high-speed centrifugation is effective in clearing lipemia interference in serum lipase activity measurement
  30. A relationship between absolute monocyte count and C-reactive protein in patients with migraine undergoing no pharmacological therapy
  31. Validation of the “Vacutainer® urinalysis preservative plus urine tube” for the determination of albumin and protein
  32. Performance evaluation of a novel automated HIV Ag/Ab chemiluminescence immunoassay
  33. SLC26A4 genotypes associated with enlarged vestibular aqueduct malformation in south Italian children with sensorineural hearing loss
  34. Is cystatin C level altered in women with polycystic ovary syndrome?
  35. Venous thromboembolism in a patient with persistent inhibitor to coagulation factor V – a case report
  36. Free light chains nephelometric assay: human urine stability in different storage conditions
  37. Comparing the viscoelastomeric fibrin polymerization assays FIBTEM® (ROTEM) vs. Functional Fibrinogen® (TEG): or why is a higher threshold for fibrinogen substitution better than a lower one?
  38. Reply to: Comparing the visco-elastomeric fibrin polymerization assays FIBTEM® (ROTEM) vs. Functional Fibrinogen® (TEG): or why is a higher threshold for fibrinogen substitution better than a lower one? By Schöchl et al.
  39. Congress Abstracts
  40. 5th Slovenian Congress of Clinical Chemistry and Laboratory Medicine
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 5.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2015-0218/html
Button zum nach oben scrollen